{"product_id":"lag3-il-2-reporter-lentivirus-set-bhv19400272","title":"LAG3\/IL-2 Reporter Lentivirus Set","description":"\u003cdiv class=\"bhp-desc\"\u003e\n\u003cstyle\u003e.bhp-desc{font-size:16px;color:#1a1a1a;line-height:1.7}.bhp-desc h2{font-size:18px;font-weight:700;color:#003366;margin:24px 0 10px;padding-bottom:6px;border-bottom:2px solid #003366}.bhp-desc p{margin:0 0 12px}.bhp-desc ul{margin:0 0 12px 22px}.bhp-desc li{margin:0 0 6px}\u003c\/style\u003e\n\u003ch2\u003e\u003cstrong\u003eBackground\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eLAG3 (lymphocyte-activation gene 3) is a co-inhibitory immune checkpoint receptor expressed on activated T cells, regulatory T cells, and other lymphocytes. By binding ligands such as MHC class II and fibrinogen-like protein 1, LAG3 transmits inhibitory signals that dampen T cell activation, proliferation, and cytokine production, contributing to peripheral tolerance and limiting excessive immune responses. In tumors, sustained LAG3 expression marks exhausted T cells and supports immune evasion. LAG3 is a validated immunotherapy target, and antibodies that block LAG3 are being developed to restore antitumor T cell function, often in combination with other checkpoint inhibitors.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eProduct Description \u0026amp; Applications\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThe LAG3\/IL-2 Reporter Lentivirus Set is a two-component immunotherapy reporter system for studying the LAG3 immune checkpoint. One lentivirus constitutively expresses the human LAG3 receptor; the second carries an IL-2-responsive dual reporter combining Gaussia luciferase with a fluorescent protein (eGFP or mCherry). Ligand engagement of LAG3 suppresses IL-2-driven reporter expression, while checkpoint inhibitors that block LAG3 restore the signal, providing a quantitative readout of checkpoint blockade. Sequential transduction with puromycin and blasticidin selection generates a dual-stable effector cell line. The system is used to evaluate LAG3-targeting antibodies and to monitor T cell activation in immuno-oncology research. Supplied as high-titer, VSV-G pseudotyped lentiviral particles suitable for difficult-to-transfect cells, including primary and thawed cells.\u003c\/p\u003e\n\u003ch2\u003e\u003cstrong\u003eAbout This Product\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp\u003eThis 2-vial immunotherapy reporter system consists of a \u003cstrong\u003eVial 1 Receptor Lentivirus\u003c\/strong\u003e encoding human LAG3 under a constitutive promoter with antibiotic selection, and a \u003cstrong\u003eVial 2 Reporter Lentivirus\u003c\/strong\u003e encoding tandem NFAT (or NF-κB) response elements driving a dual reporter (Gaussia Luciferase + eGFP, Gaussia Luciferase + mCherry). Sequential transduction and selection generates a dual-stable effector cell line that responds quantitatively to receptor stimulation with a ratiometric fluorescent + bioluminescent readout.\u003c\/p\u003e\n\u003cp\u003eSecreted Gaussia luciferase (where included) accumulates in conditioned media, enabling kinetic sampling without cell lysis. The combined fluorescent and luminescent outputs allow parallel microscopy-based visualization and plate-reader luminometry from the same cell population — providing assay redundancy and flexibility for potency testing formats compliant with regulatory expectations for cell-based functional assays.\u003c\/p\u003e\n\u003c\/div\u003e","brand":"LipExoGen Biotech","offers":[{"title":"Gaussia Luciferase + eGFP \/ Puromycin + Blasticidin \/ 2x10^6 per vial","offer_id":53251618439533,"sku":"TRV-0024-SET1","price":1200.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/Immunotherapy-Reporter-Set-Construct-Diagrams-1_11e09355-cad1-41a4-a956-d051578f27a2.jpg?v=1776934219","url":"https:\/\/www.ebiohippo.com\/products\/lag3-il-2-reporter-lentivirus-set-bhv19400272","provider":"BioHippo","version":"1.0","type":"link"}